Xentria Revenue, Growth & Competitor Profile

Company Profile & Annual Report for Xentria

Access the complete profile.

Xentria Fast Facts

Revenue	$1 - $10 million    See Exact Annual Revenue
Employees	1 - 10Exact Company Size
Primary Industry	5417 Scientific Research & Development Services
Address	8700 W Bryn Mawr Avenue Suite 600s Chicago, IL 60631

Note: Revenues for privately held companies are statistical evaluations.


Xentria's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • Xentria's annual revenues are $1 - $10 million (see exact revenue data)
• What industry is the company in?
  • Xentria is classified as operating in the Scientific Research & Development Services industry, NAICS Code 5417.

Xentria Annual Revenue and Growth Rate

Xentria	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2025	$1 - $10 million Details in Premium Report
2024
2023
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Xentria's revenues are gauged from an analysis of company filings.

Xentria's Income Statement (based on Industry Averages)

Xentria P&L	$ Millions
Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit

Trademark Applications

Trademark applications show the products and services that Xentria is developing and marketing. Xentria doesn't have any recent trademark applications, indicating Xentria is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
TRINSERRA house mark for a full line of biologic, biosimilar, and pharmaceutical preparations; house mark for a full line of biologics; house mark for a full line of biosimilars; house mark for a full line of pharmaceuticals; house mark for a full line of biologic, biosimilar, and pharmaceutical products; biologic, biosimilar, and pharmaceutical preparations for the treatment of bone disease; biologic, biosimilar, and pharmaceutical preparations for use in the treatment of oncological and metabolic diseases and disorders, and complications associated therewith; biologic, biosimilar, and pharmaceutical preparations for the treatment of diabetes; biologic, biosimilar, and pharmaceutical preparations for treatment and prevention of autoimmune diseases and autoimmune disorders; biologic, biosimilar, and pharmaceutical oncology preparations; anti-inflammatories; biologic, biosimilar, and pharmaceutical preparations for the treatment of immune system related diseases and disorders; biologic, biosimilar, and pharmaceutical preparations for use in dermatology; biologic, biosimilar, and pharmaceutical preparations for use in rheumatology; biologic, biosimilar, and pharmaceutical preparations, namely, anti-interleukin-6 (IL-6) receptor monoclonal antibody for the treatment of disease caused by IL-6 production; biologic, biosimilar, and pharmaceutical preparations, namely, biopharmaceuticals based on human monoclonal antibodies for the treatment of immune and inflammatory diseases and disorders	04/29/2020
XENTRIA house mark for a full line of biologic, biosimilar, and pharmaceutical preparations; house mark for a full line of biologics; house mark for a full line of biosimilars; house mark for a full line of pharmaceuticals; house mark for a full line of biologic, biosimilar, and pharmaceutical products; biologic, biosimilar, and pharmaceutical preparations for the treatment of bone disease; biologic, biosimilar, and pharmaceutical preparations for use in the treatment of oncological and metabolic diseases and disorders, and complications associated therewith; biologic, biosimilar, and pharmaceutical preparations for the treatment of diabetes; biologic, biosimilar, and pharmaceutical preparations for treatment and prevention of autoimmune diseases and autoimmune disorders; biologic, biosimilar, and pharmaceutical oncology preparations; anti-inflammatories; biologic, biosimilar, and pharmaceutical preparations for the treatment of immune system related diseases and disorders; biologic, biosimilar, and pharmaceutical preparations for use in dermatology; biologic, biosimilar, and pharmaceutical preparations for use in rheumatology; biologic, biosimilar, and pharmaceutical preparations, namely, anti-interleukin-6 (IL-6) receptor monoclonal antibody for the treatment of disease caused by IL-6 production; biologic, biosimilar, and pharmaceutical preparations, namely, biopharmaceuticals based on human monoclonal antibodies for the treatment of immune and inflammatory diseases and disorders	04/29/2020

See all trademarks and details in the Full Report.

Market Share of Xentria's Largest Competitors

A competitive analysis shows these companies are in the same general field as Xentria, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
LEIDOS	Denver, CO	100
NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA	Albuquerque, NM	30
INC RESEARCH	Raleigh, NC	27
RESEARCH FOUNDATION FOR STATE UNIVERSITY OF NEW YORK	Albany, NY	17
FLUOR MARINE PROPULSION	West Mifflin, PA	15
SYNEOS HEALTH	Raleigh, NC	13
ILLUMINA	San Diego, CA	12
UT-BATTELLE	Oak Ridge, TN	11
PRA HOLDINGS	Raleigh, NC	11

Nearby Competitors

These companies are similar in business line and location to Xentria. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
FERMI RESEARCH ALLIANCE	Chicago, IL	100
PHARMACANN	Chicago, IL	33
XERIS PHARMACEUTICALS	Chicago, IL	20
HEALTH UTILITY NETWORK	Chicago, IL	13
CHAPIN HALL CENTER FOR CHILDREN	Chicago, IL	9
IIT RESEARCH INSTITUTE	Chicago, IL	6

Other Companies at 8700 W Bryn Mawr Avenue, Chicago IL

Company	Headquarters	Revenue ($ MM)
MILK PRODUCTS HOLDINGSNORTH AM	Chicago, IL	100
WESTWIND MORTGAGE BANCORP	Chicago, IL	9

Future Competition: Xentria's Fastest Growing Competitors

These companies are in the same general field as Xentria and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)